Subcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCC

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

Related Keywords

Mexico ,New York ,United States ,Saby George ,Jacobs School Of Medicine ,Network Clinical Trials ,Roswell Park Comprehensive Cancer Center ,University Of Buffalo ,Biomedical Sciences ,Jacobs School ,South America ,Nivolumab ,Opdivo ,Rhuph20 ,Nivolumab Noninferiority Of Exposures ,Cavgd28 ,Cminss ,Intravenous Nivolumab ,Iv Nivolumab ,Subcutaneous Nivolumab ,2024 Genitourinary Cancers Symposium ,Phase 3 Checkmate 67t Trial ,Nccrcc ,Clear Cell Renal Carcinoma ,